FUTURE MEETINGS

With participation from NIDA and DEA, FDA will convene a hearing on the scheduling criteria for benzodiazepines and benzodiazepine- related substances. The purpose of this hearing is to gather evidence on possible ways to distinguish the abuse potential of different benzodiazepines, which will assist the federal government in scheduling reviews under the Controlled Substances Act.

Date: September 11 and 12, 1997, from 9 a.m. to 4 p.m.

Location:

Renaissance Hotel
999 Ninth Street, NW
Washington, DC 20001-9000

For Further Information Contact:

Nicholas P. Reuter, Office of Health Affairs (HFY-20), FDA, 5600 Fishers Lane, Room 15-22, Rockville, MD 20857, (301) 827-1696, FAX (301) 443-0232, e-mail at nreuter@bangate.fda.gov.

WORKSHOP ON THALIDOMIDE

FDA, NIH, and CDC are cosponsoring a public workshop on the potential benefits and risks of thalidomide. The purpose of the meeting is to provide a public forum to assess the emerging research opportunities, potential clinical applications, and accompanying risk associated with the use of thalidomide.

Date: September 9 and 10, 1997

Location:

The Natcher Auditorium
National Institutes of Health
Bethesda, MD

Continuing Medical Education (CME) credit will be offered.

For Additional Information Contact:

Prospect Associates, (301) 468-MEET (6338), FAX (301) 770-5164.

FDA/Website Management Staff